Boston, MA 06/12/2014 (wallstreetpr) – Boston Scientific Corporation’s (NYSE:BSX) system developed for the treatment of Parkinson’s disease has successfully demonstrated an improving effect on patients who got treated with the same. Boston’s Vercise™ Deep Brain Stimulation (DBS) has shown that compared to conventional pulses, shorter simulation pulses may prove to be more effective. Vercise™ Deep Brain Stimulation (DBS) is the only system which is available on a commercial level with the technology to generate shorter simulation pulses.
The study on Parkinson’s:
The results of the study conducted over a one year period, were presented in Stockholm, Sweden, at the Eighteenth International Congress of Parkinson’s Disease & Movement Disorders.
The study involved 15 patients suffering from Parkinson’s disease, who got the Boston Scientific Corporation’s (NYSE:BSX) Vercise DBS System implanted. The device uses electrical signals to stimulate some of the specific areas of the patient’s brain and helps in reducing the symptoms of Parkinson’s disease which is affecting around 6.3 million people worldwide. The Vercise DBS is the only system with a rechargeable battery that has got a life of around 25 years, as a result of which patients are relieved of going for any battery replacement surgery.
The shorter simulation pulses generated by the device are also energy efficient and require less electricity. Moreover, the shorter simulation pulses provide a large therapeutic window which leads to avoiding any side effects due to simulation.
The study showed an improvement of 62% in motor function for one year period and a reduction in the medication taken by patients by 58%, as compared to the level of medication take by patients before the treatment. The study is expected to continue for a further five year period.
Availability of Vercise DBS:
The system is currently available for sale & use in Israel, Europe, Australia and some Latin American countries. In the case of the U.S., the system is still under investigation & trail and is not available for sale as well as for use. The system has got approval from the Australia Therapeutic Goods Administration i.e. TGA and also from CE Mark.
